Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial

Daniel J. Wallace, Richard A. Furie, Yoshiya Tanaka, Kenneth C. Kalunian, Marta Mosca, Michelle Petri, Thomas Dörner, Mario H. Cardiel, Ian N. Bruce, Elisa Gomez, Tara Carmack, Amy M. DeLozier, Jonathan M. Janes, Matthew D. Linnik, Stephanie de Bono, Maria E. Silk, Robert W. Hoffman

Research output: Contribution to journalArticle

Abstract

Background: Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus. Methods: In this double-blind, multicentre, randomised, placebo-controlled, 24-week phase 2 study, patients were recruited from 78 centres in 11 countries. Eligible patients were aged 18 years or older, had a diagnosis of systemic lupus erythematosus, and had active disease involving skin or joints. We randomly assigned patients (1:1:1) to receive once-daily baricitinib 2 mg, baricitinib 4 mg, or placebo for 24 weeks. The primary endpoint was the proportion of patients achieving resolution of arthritis or rash at week 24, as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT02708095. Findings: Between March 24, 2016, and April 27, 2017, 314 patients were randomly assigned to receive placebo (n=105), baricitinib 2 mg (n=105), or baricitinib 4 mg (n=104). At week 24, resolution of SLEDAI-2K arthritis or rash was achieved by 70 (67%) of 104 patients receiving baricitinib 4 mg (odds ratio [OR] vs placebo 1·8, 95% CI 1·0–3·3; p=0·0414) and 61 (58%) of 105 patients receiving baricitinib 2 mg (OR 1·3, 0·7–2·3; p=0·39). Adverse events were reported in 68 (65%) patients in the placebo group, 75 (71%) patients in the baricitinib 2 mg group, and 76 (73%) patients in the baricitinib 4 mg group. Serious adverse events were reported in ten (10%) patients receiving baricitinib 4 mg, 11 (10%) receiving baricitinib 2 mg, and five (5%) receiving placebo; no deaths were reported. Serious infections were reported in six (6%) patients with baricitinib 4 mg, two (2%) with baricitinib 2 mg, and one (1%) with placebo. Interpretation: The baricitinib 4 mg dose, but not the 2 mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib. This study provides the foundation for future phase 3 trials of JAK1/2 inhibition with baricitinib as a new potential oral therapy for systemic lupus erythematosus. Funding: Eli Lilly and Company.

Original languageEnglish (US)
Pages (from-to)222-231
Number of pages10
JournalThe Lancet
Volume392
Issue number10143
DOIs
StatePublished - Jul 21 2018

Fingerprint

Systemic Lupus Erythematosus
Placebos
baricitinib
Exanthema
Arthritis
Janus Kinase 1
Odds Ratio
Safety
Joint Diseases
Standard of Care
Double-Blind Method
Skin Diseases
Signs and Symptoms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Wallace, D. J., Furie, R. A., Tanaka, Y., Kalunian, K. C., Mosca, M., Petri, M., ... Hoffman, R. W. (2018). Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet, 392(10143), 222-231. https://doi.org/10.1016/S0140-6736(18)31363-1

Baricitinib for systemic lupus erythematosus : a double-blind, randomised, placebo-controlled, phase 2 trial. / Wallace, Daniel J.; Furie, Richard A.; Tanaka, Yoshiya; Kalunian, Kenneth C.; Mosca, Marta; Petri, Michelle; Dörner, Thomas; Cardiel, Mario H.; Bruce, Ian N.; Gomez, Elisa; Carmack, Tara; DeLozier, Amy M.; Janes, Jonathan M.; Linnik, Matthew D.; de Bono, Stephanie; Silk, Maria E.; Hoffman, Robert W.

In: The Lancet, Vol. 392, No. 10143, 21.07.2018, p. 222-231.

Research output: Contribution to journalArticle

Wallace, DJ, Furie, RA, Tanaka, Y, Kalunian, KC, Mosca, M, Petri, M, Dörner, T, Cardiel, MH, Bruce, IN, Gomez, E, Carmack, T, DeLozier, AM, Janes, JM, Linnik, MD, de Bono, S, Silk, ME & Hoffman, RW 2018, 'Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial', The Lancet, vol. 392, no. 10143, pp. 222-231. https://doi.org/10.1016/S0140-6736(18)31363-1
Wallace, Daniel J. ; Furie, Richard A. ; Tanaka, Yoshiya ; Kalunian, Kenneth C. ; Mosca, Marta ; Petri, Michelle ; Dörner, Thomas ; Cardiel, Mario H. ; Bruce, Ian N. ; Gomez, Elisa ; Carmack, Tara ; DeLozier, Amy M. ; Janes, Jonathan M. ; Linnik, Matthew D. ; de Bono, Stephanie ; Silk, Maria E. ; Hoffman, Robert W. / Baricitinib for systemic lupus erythematosus : a double-blind, randomised, placebo-controlled, phase 2 trial. In: The Lancet. 2018 ; Vol. 392, No. 10143. pp. 222-231.
@article{601fdefd55e14eb387521e03093b3dd0,
title = "Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial",
abstract = "Background: Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus. Methods: In this double-blind, multicentre, randomised, placebo-controlled, 24-week phase 2 study, patients were recruited from 78 centres in 11 countries. Eligible patients were aged 18 years or older, had a diagnosis of systemic lupus erythematosus, and had active disease involving skin or joints. We randomly assigned patients (1:1:1) to receive once-daily baricitinib 2 mg, baricitinib 4 mg, or placebo for 24 weeks. The primary endpoint was the proportion of patients achieving resolution of arthritis or rash at week 24, as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT02708095. Findings: Between March 24, 2016, and April 27, 2017, 314 patients were randomly assigned to receive placebo (n=105), baricitinib 2 mg (n=105), or baricitinib 4 mg (n=104). At week 24, resolution of SLEDAI-2K arthritis or rash was achieved by 70 (67{\%}) of 104 patients receiving baricitinib 4 mg (odds ratio [OR] vs placebo 1·8, 95{\%} CI 1·0–3·3; p=0·0414) and 61 (58{\%}) of 105 patients receiving baricitinib 2 mg (OR 1·3, 0·7–2·3; p=0·39). Adverse events were reported in 68 (65{\%}) patients in the placebo group, 75 (71{\%}) patients in the baricitinib 2 mg group, and 76 (73{\%}) patients in the baricitinib 4 mg group. Serious adverse events were reported in ten (10{\%}) patients receiving baricitinib 4 mg, 11 (10{\%}) receiving baricitinib 2 mg, and five (5{\%}) receiving placebo; no deaths were reported. Serious infections were reported in six (6{\%}) patients with baricitinib 4 mg, two (2{\%}) with baricitinib 2 mg, and one (1{\%}) with placebo. Interpretation: The baricitinib 4 mg dose, but not the 2 mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib. This study provides the foundation for future phase 3 trials of JAK1/2 inhibition with baricitinib as a new potential oral therapy for systemic lupus erythematosus. Funding: Eli Lilly and Company.",
author = "Wallace, {Daniel J.} and Furie, {Richard A.} and Yoshiya Tanaka and Kalunian, {Kenneth C.} and Marta Mosca and Michelle Petri and Thomas D{\"o}rner and Cardiel, {Mario H.} and Bruce, {Ian N.} and Elisa Gomez and Tara Carmack and DeLozier, {Amy M.} and Janes, {Jonathan M.} and Linnik, {Matthew D.} and {de Bono}, Stephanie and Silk, {Maria E.} and Hoffman, {Robert W.}",
year = "2018",
month = "7",
day = "21",
doi = "10.1016/S0140-6736(18)31363-1",
language = "English (US)",
volume = "392",
pages = "222--231",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "10143",

}

TY - JOUR

T1 - Baricitinib for systemic lupus erythematosus

T2 - a double-blind, randomised, placebo-controlled, phase 2 trial

AU - Wallace, Daniel J.

AU - Furie, Richard A.

AU - Tanaka, Yoshiya

AU - Kalunian, Kenneth C.

AU - Mosca, Marta

AU - Petri, Michelle

AU - Dörner, Thomas

AU - Cardiel, Mario H.

AU - Bruce, Ian N.

AU - Gomez, Elisa

AU - Carmack, Tara

AU - DeLozier, Amy M.

AU - Janes, Jonathan M.

AU - Linnik, Matthew D.

AU - de Bono, Stephanie

AU - Silk, Maria E.

AU - Hoffman, Robert W.

PY - 2018/7/21

Y1 - 2018/7/21

N2 - Background: Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus. Methods: In this double-blind, multicentre, randomised, placebo-controlled, 24-week phase 2 study, patients were recruited from 78 centres in 11 countries. Eligible patients were aged 18 years or older, had a diagnosis of systemic lupus erythematosus, and had active disease involving skin or joints. We randomly assigned patients (1:1:1) to receive once-daily baricitinib 2 mg, baricitinib 4 mg, or placebo for 24 weeks. The primary endpoint was the proportion of patients achieving resolution of arthritis or rash at week 24, as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT02708095. Findings: Between March 24, 2016, and April 27, 2017, 314 patients were randomly assigned to receive placebo (n=105), baricitinib 2 mg (n=105), or baricitinib 4 mg (n=104). At week 24, resolution of SLEDAI-2K arthritis or rash was achieved by 70 (67%) of 104 patients receiving baricitinib 4 mg (odds ratio [OR] vs placebo 1·8, 95% CI 1·0–3·3; p=0·0414) and 61 (58%) of 105 patients receiving baricitinib 2 mg (OR 1·3, 0·7–2·3; p=0·39). Adverse events were reported in 68 (65%) patients in the placebo group, 75 (71%) patients in the baricitinib 2 mg group, and 76 (73%) patients in the baricitinib 4 mg group. Serious adverse events were reported in ten (10%) patients receiving baricitinib 4 mg, 11 (10%) receiving baricitinib 2 mg, and five (5%) receiving placebo; no deaths were reported. Serious infections were reported in six (6%) patients with baricitinib 4 mg, two (2%) with baricitinib 2 mg, and one (1%) with placebo. Interpretation: The baricitinib 4 mg dose, but not the 2 mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib. This study provides the foundation for future phase 3 trials of JAK1/2 inhibition with baricitinib as a new potential oral therapy for systemic lupus erythematosus. Funding: Eli Lilly and Company.

AB - Background: Patients with systemic lupus erythematosus have substantial unmet medical need. Baricitinib is an oral selective Janus kinase (JAK)1 and JAK2 inhibitor that we hypothesised might have therapeutic benefit in patients with systemic lupus erythematosus. Methods: In this double-blind, multicentre, randomised, placebo-controlled, 24-week phase 2 study, patients were recruited from 78 centres in 11 countries. Eligible patients were aged 18 years or older, had a diagnosis of systemic lupus erythematosus, and had active disease involving skin or joints. We randomly assigned patients (1:1:1) to receive once-daily baricitinib 2 mg, baricitinib 4 mg, or placebo for 24 weeks. The primary endpoint was the proportion of patients achieving resolution of arthritis or rash at week 24, as defined by Systemic Lupus Erythematosus Disease Activity Index-2000 (SLEDAI-2K). Efficacy and safety analyses included all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, number NCT02708095. Findings: Between March 24, 2016, and April 27, 2017, 314 patients were randomly assigned to receive placebo (n=105), baricitinib 2 mg (n=105), or baricitinib 4 mg (n=104). At week 24, resolution of SLEDAI-2K arthritis or rash was achieved by 70 (67%) of 104 patients receiving baricitinib 4 mg (odds ratio [OR] vs placebo 1·8, 95% CI 1·0–3·3; p=0·0414) and 61 (58%) of 105 patients receiving baricitinib 2 mg (OR 1·3, 0·7–2·3; p=0·39). Adverse events were reported in 68 (65%) patients in the placebo group, 75 (71%) patients in the baricitinib 2 mg group, and 76 (73%) patients in the baricitinib 4 mg group. Serious adverse events were reported in ten (10%) patients receiving baricitinib 4 mg, 11 (10%) receiving baricitinib 2 mg, and five (5%) receiving placebo; no deaths were reported. Serious infections were reported in six (6%) patients with baricitinib 4 mg, two (2%) with baricitinib 2 mg, and one (1%) with placebo. Interpretation: The baricitinib 4 mg dose, but not the 2 mg dose, significantly improved the signs and symptoms of active systemic lupus erythematosus in patients who were not adequately controlled despite standard of care therapy, with a safety profile consistent with previous studies of baricitinib. This study provides the foundation for future phase 3 trials of JAK1/2 inhibition with baricitinib as a new potential oral therapy for systemic lupus erythematosus. Funding: Eli Lilly and Company.

UR - http://www.scopus.com/inward/record.url?scp=85050110746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050110746&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(18)31363-1

DO - 10.1016/S0140-6736(18)31363-1

M3 - Article

C2 - 30043749

AN - SCOPUS:85050110746

VL - 392

SP - 222

EP - 231

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 10143

ER -